Ionis Pharmaceuticals (IONS) Cost of Revenue (2018 - 2026)

Ionis Pharmaceuticals' Cost of Revenue history runs 9 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 103.9% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $17.4 million (up 65.55% YoY), while the FY2025 annual figure was $15.9 million, up 41.85% from the prior year.
• Cost of Revenue was $3.0 million for Q1 2026 at Ionis Pharmaceuticals, down from $8.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $8.0 million in Q4 2025 to a low of $1.1 million in Q3 2024.
• Historically, Cost of Revenue has averaged $3.1 million across 5 years, with a median of $3.0 million in 2026.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue slumped 67.79% in 2023, then surged 118.3% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $3.7 million in 2022, then declined by 16.93% to $3.1 million in 2023, then advanced by 25.08% to $3.8 million in 2024, then surged by 107.75% to $8.0 million in 2025, then plunged by 62.51% to $3.0 million in 2026.
• The last three Cost of Revenue figures came in at $3.0 million (Q1 2026), $8.0 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.